DrugInformations.org

Fifteen percent to 20 percent of people worldwide suffer from migraines excruciating headaches often presaged by dramatic sensations, or “auras.” By studying a rare, inherited form of migraine, researchers at Vanderbilt University Medical Center have found clues to the biological basis of the painful, debilitating disorder. In the Proceedings of the National Academy of Sciences, Alfred George Jr., M.D.

More: continued here

No Comments »

Nearly everyone has experienced the acute, short-lived pain that occurs after a mild injury, but recent surveys reveal that more than 20% of the population has a chronic pain condition (i.e., pain that has lasted for 3 months or more) and for which treatment is often not very effective (e.g., low back pain, fibromyalgia, migraine headaches). Acute and chronic pain conditions have huge socio-economic costs.

More: continued here

No Comments »

A Webinar hosted by TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate. The company’s President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by: Tony Yaksh, Ph.D.

More: continued here

No Comments »

Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, singleblinded, Controlled investigational study using its neurostimulation system to stimulate the occipital nerves as a potential approach to treating medically refractory chronic migraines will be presented during a late-breaking session at the annual scientific meeting of the American Headache Society (AHS) tomorrow in Boston.

More: continued here

No Comments »

A novel electronic device designed to “zap” away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at The Ohio State University Medical Center. Results of the study, presented TODAY (6/27) at the annual American Headache Society meeting in Boston, found that the experimental device is safe and effective in eliminating headaches when administered during the onset of the migraine.

More: continued here

No Comments »

Headache frustrations are set to ease, thanks to a new range of patient leaflets. Produced by Lifting The Burden, the World Health Organization’s Global Campaign to Reduce the Burden of Headache Worldwide, they will help sufferers understand and manage their headache more effectively. Almost all of us will have had a headache, but for many people it is more than just an irritant.

More: continued here

No Comments »

There are some 30 million Americans who suffer from migraine headaches.* Researchers at Ohio State University Medical Center have unveiled a new device that can control the pain of migraine headaches with no drugs, no injections, and no side effects. In fact this device is as easy as touching a button. After nearly eight years of development the migraine zapper could be on the market in a matter of months.

More: continued here

No Comments »

Merck & Co., Inc. announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.

More: continued here

No Comments »

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.

More: continued here

No Comments »

Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.

More: continued here

No Comments »